资讯

GlobalData on MSN2 天
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
Dermatology Advisor1 天
Dupixent Gains Approval for Bullous Pemphigoid
The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
FDA approves Dupixent for bullous pemphigoid
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
The American Journal of Managed Care7 天
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...
Medical Dialogues5 天
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
Monthly Prescribing Reference8 天
Dupixent Gains Approval for Bullous Pemphigoid - MPR
Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions.
Healio8 天
FDA approves Dupixent for bullous pemphigoid - Healio
The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s ...
Too Old to Operate3 天
FDA Approves Dupixent for Bullous Pemphigoid
TUESDAY, June 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on ...